Fredun Pharmaceuticals Limited has filed its quarterly compliance certificate with BSE Limited for the quarter ended March 31, 2026, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The pharmaceutical company submitted the mandatory documentation on April 6, 2026, ensuring adherence to market regulations.

Regulatory Compliance Filing

The company submitted its certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 to BSE Limited's Listing Department. Managing Director Fredun Nariman Medhora signed the compliance document, which was digitally authenticated on April 6, 2026. The filing included a certificate dated April 1, 2026, from the company's SEBI registered registrar and share transfer agent.

Share Transfer Agent Confirmation

Purva Sharegistry (India) Pvt. Ltd., serving as the company's registrar and share transfer agent, provided the required confirmation certificate. The agent, registered with SEBI under registration number INR000001112 as a Category 1 Registrar, confirmed compliance with all dematerialization procedures during the quarter. Ms. Deepali Gaonkar, Compliance Officer at Purva Sharegistry, signed the confirmation document.

Dematerialization Activity Details

During the quarter from January 1, 2026 to March 31, 2026, the company processed dematerialization of share certificates for two shareholders:

The total dematerialization activity for the quarter involved 1,000 shares across two certificates, both processed on the same date in February 2026.

Regulatory Adherence

The registrar confirmed that all security certificates received for dematerialization were properly verified, mutilated, and cancelled after due verification by the depository participant. The names of the depositories were substituted in the register of members as registered owners within prescribed timelines. This compliance ensures that the dematerialized securities maintain their listing status on stock exchanges where the company's earlier issued securities are traded.

The quarterly filing demonstrates Fredun Pharmaceuticals' commitment to maintaining regulatory compliance and transparent reporting to market authorities and stakeholders.

Fredun Pharmaceuticals Limited has filed mandatory insider trading disclosure documents with BSE Limited following the recent conversion of 1,06,668 warrants into equity shares by promoter Fredun Nariman Medhora. The disclosure, submitted on March 26, 2026, complies with Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015.

Warrant Conversion and Share Allotment Details

The Board of Directors meeting held on March 25, 2026, from 05:00 p.m. to 05:35 p.m., approved the conversion of warrants after receiving the requisite balance consideration of Rs. 10,00,01,250. Mr. Fredun Nariman Medhora, Managing Director and promoter, exercised his conversion rights for 1,06,668 warrants into equivalent equity shares.

Shareholding Pattern Changes

According to the SEBI Form C disclosure, the warrant conversion has resulted in significant changes to the promoter's shareholding pattern. Prior to the conversion, Fredun Nariman Medhora held 1,79,672 equity shares representing 3.35% of the company's shareholding.

Regulatory Compliance and Documentation

The company has fulfilled all disclosure requirements under SEBI (Prohibition of Insider Trading) Regulations, 2015, with Company Secretary and Compliance Officer Vaishnavi Sahu submitting the necessary documentation to BSE Limited. The conversion follows the preferential issue framework established under Chapter V of the SEBI ICDR Regulations 2018.

The newly allotted equity shares have been issued in dematerialized form and rank pari passu with existing equity shares in all respects. The warrant allotment was originally made pursuant to shareholder approval obtained in the Extra-Ordinary General Meeting held on October 22, 2025.